An observational study in Retinitis Pigmentosa and Eye Diseases, sponsored by Sensor Technology for Deafblind. Recruiting at 1 site in Russia. Open to participants aged 14 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by Sensor Technology for Deafblind · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This natural history study of patients with EYS mutations from Russia and former CIS (Commonwealth of Independent States) territories will accelerate the development of outcome measures for clinical trials. Sensitive, reliable outcome measures of retinal degeneration will greatly facilitate development of treatments for retinitis pigmentosa due to EYS mutations. This approach helps to develop experimental treatment protocol, and assessing its effectiveness.
The goals and expected impact of this natural history study are to:
281 studies on the registry are indexed under Retinitis Pigmentosa; 74 are open to participants now.
This study's planned enrollment of 45 is below the median of 52 across 89 observational studies indexed under Retinitis Pigmentosa.
Browse Retinitis Pigmentosa studies →Sensor Technology for Deafblind is the lead sponsor of 3 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Potential eligibility may be assessed as part of a routine care examination by an investigator prior to obtaining informed consent, as part of usual care, by referral from another physician, or self-referral.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Screening Group A: At least 2 disease-causing variants in the EYS gene which are homozygous or heterozygous in trans, based on a report from a clinically-certified lab (or a report from a research lab that has been pre-approved by the Study Committee) Screening Group B: Only 1 disease-causing variant in the EYS gene, based on a report from a clinically-certified lab (or a report from a research lab which has been pre-approved by the Study Committee) Screening Group C: At least 2 disease-causing variants in the EYS gene which are unknown phase, based on a report from a clinically-certified lab (or a report from a research lab which has been pre-approved by the Study Committee) Note pertaining to all Screening Groups: if a participant has a variant(s) of unknown significance, he/she would still qualify as long as there is at least 1 disease-causing variant(s) on the EYS gene.
Ocular Inclusion Criteria:
Both eyes must meet all of the following:
Exclusion Criteria:
Ocular exclusion Criteria:
If either eye has any of the following, the participant is not eligible:
Participants with the better eye Screening Visit decimal visual acuity of 0.4 or more and visual field diameter 10 degrees or more in every meridian of the central field.
Diagnostic Test: Whole exome/genome sequencing
Participants with the better eye Screening Visit decimal visual acuity 0.15 - 0.35 and visual field diameter less than 10 degrees in any meridian of the central field)
Diagnostic Test: Whole exome/genome sequencing
Participants with the better eye Screening Visit decimal visual acuity 0.14 or less.
Diagnostic Test: Whole exome/genome sequencing
Next generation sequencing and segregation analysis or long read sequencing for confirmation of biallelic mutations (in trans-position)
Change in Visual Field Sensitivity
Measured by static perimetry with topographic analysis and assessed by a certified reading center for cohorts 1 and 2.
Time frame: Baseline and every year until study completion (4 years)
Change in Retinal Function
Measured by full-field electroretinogram (ERG) amplitudes and timing in response to rod- and cone-specific stimuli for cohorts 1 and 2.
Time frame: Baseline and 4 year follow-up visit.
Change in Best Corrected Visual Acuity
Measured on Golovina-Sivtsev charts
Time frame: Screening visit and every year until study completion (4 years) for cohort 1&2. Screening visit and 48 month follow-up for cohort 3.
Change in Mean Retinal Sensitivity
Measured by fundus-guided microperimetry (MP) and assessed by a certified reading center for cohorts 1 and 2.
Time frame: Baseline and every year until study completion (4 years)
Change in Best Corrected Low Luminance visual acuity
Measured by letter score
Time frame: Screening visit and every year until study completion (4 years) for cohort 1&2. Screening visit and 48 month follow-up for cohort 3.
Change in Contrast Sensitivity Function
Measured by Zebra software for cohorts 1 and 2.
Time frame: Baseline and every year until study completion (4 years).
Change in Ellipsoid zone (EZ) area
Measured by spectral domain optical coherence tomography (SD-OCT) and assessed by a certified expert
Time frame: Baseline and every year until study completion (4 years) for cohorts 1 and 2. Baseline and 4 year follow-up for cohort 3.
Explore qualitative and quantitative categorization of Fundus Autofluorescence (FAF) pattern
Assessed by a certified expert
Time frame: Baseline and every year until study completion (4 years) for cohorts 1 and 2. Baseline and 4 year follow-up for cohort 3.
Patient Reported Outcomes for Vision Cohorts 1, 2 and 3
Measured by modified MRDQ (Michigan Retinal Degeneration Questionnaire)
Time frame: Baseline and 4 year follow-up visit
Plan to share: Yes — A de-identified database will be placed in the public domain on the Oftalmic public website after the completion of each protocol and publication of the manuscript.
Supporting information: Clinical study report
Time frame: After manuscript is published
Access criteria: Users accessing data must enter an email address
No publications or documents are linked to this record.
Started Nov 2025 (actual). Primary completion is estimated for Dec 2029, 49 months after the start.
Of 49 observational studies under Retinitis Pigmentosa, half reached primary completion within 71 months of starting (the median), counting those still running; a quarter within 23. This study's planned 49 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Sensor Technology for Deafblind